Home
About
Overview
Sharing Data
ORCID
Help
History (13)
A trial of education, prompts, and opinion leaders to improve prescription of lipid modifying therapy by primary care physicians for patients with ischemic heart disease.
Arsenicals
Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition.
C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis.
Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children.
See All 13 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children.
Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children. Pediatrics. 2021 05; 147(5).
View in:
PubMed
subject areas
Anti-Inflammatory Agents
Antiviral Agents
Biological Products
Biomarkers
Child
Child, Preschool
Female
Humans
Male
Systemic Inflammatory Response Syndrome
Treatment Outcome
Ventricular Dysfunction, Left
authors with profiles
Andrew M. Atz
Elizabeth H. Mack
Allison Ross Eckard